Background
==========

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder with axonal degeneration of the central nervous system. Although the etiology of MS is not well understood, the interplay of both genetic and environmental factors is the most likely hypothesis \[[@B1]-[@B5]\]. With regard to the role of genetic factors, genome-wide association studies (GWAS) have confirmed more than 100 loci with genome-wide significance \[[@B6]-[@B8]\]. According to the most recent GWAS, approximately 22% of signals overlapped at least one other autoimmune disease signal \[[@B8]\], However, all loci except HLA showed modest odds-ratio (OR) in the range of 1.1-1.3 \[[@B9]\]. In particular the association between MS and the *HLA-DRB1\*15:01* haplotype has been shown to be strong.

A number or reports have suggested a possible role of oxidative stress and lipid peroxidation in the inflammatory processes and in the pathogenesis of MS \[[@B10]-[@B40]\]. Reactive oxygen species (ROS) generated in excess primarily by macrophages and microglia, have been implicated as mediators of demyelination and axonal damage \[[@B10]\]. The main results of studies on oxidative stress markers in the brain, spinal cord, and CSF, both in MS patients and in experimental autoimmune encephalomyelitis (EAE) are summarized in a table included as an Additional file [1](#S1){ref-type="supplementary-material"}: Table S1.

NAD(P)H dehydrogenase, quinone 1 (NQO1) is a phase II detoxification enzyme that catalyzes the one-electron reduction of endogenous and exogenous quinones, preventing their participation in redox cycling and subsequent generation of reactive oxygen species. This enzyme is encoded by the *NQO1* gene (chromosome 16q22.1, Gene Identity 1728) (link <http://www.ncbi.nlm.nih.gov/gene/1728>). The enzymatic activity of NQO1 depends fundamentally on a single nucleotide polymorphism (SNP) at the NQO1 locus, rs1800566 (C609T), which produces a proline-to-serine substitution at amino acid 187 (P187S) (link <http://www.ncbi.nih.gov/pubmed/9000600>). Individuals with rs1800566TT genotype completely lack NQO1 activity, whereas those with rs1800566C/T genotype present approximately threefold decreased enzyme activity \[[@B41]\].

Although *NQO1* polymorphisms are not mentioned among the possible susceptibility genes in GWAS studies, the possible role of oxidative stress in the pathogenesis of MS makes it reasonable to analyse the possible relationship between *NQO1* gene polymorphisms and the risk of MS. Moreover, NQO1 has been found to be markedly up-regulated in active demyelinating MS lesions \[[@B13],[@B14]\] Stavropoulou et al. \[[@B42]\], in a case--control association study involving 231 MS patients and 380 controls, reported an association between the rs1800566CT and TT genotypes and the risk of developing MS, and a higher incidence of rs1800566CT genotype in patients with primary progressive MS. The aim of the present study was to replicate the findings by Stavropoulou et al. \[[@B42]\] in the Spanish population.

Methods
=======

Patients and controls
---------------------

We studied 290 unrelated Caucasian Spanish patients who fulfilled McDonald's criteria for definite MS \[[@B43]\], with no other previous neurological diseases. MS patients were recruited from the "Multiple Sclerosis Association of Madrid" (n = 165 cases), the Health Areas of the La-Mancha-Centro Hospital (Alcázar de San Juan, Ciudad Real, n = 65 cases), and University Hospitals "Doce de Octubre" (Madrid, n = 30 cases), and "Príncipe de Asturias" (Alcalá de Henares, Madrid, n = 30 cases). Most of these patients had participated in previous studies of genetic association with MS risk \[[@B44]-[@B48]\]. The control group was composed of 310 healthy unrelated Caucasian Spanish individuals (students or professors from the University of Extremadura) gender and age-matched with the patients. Ethnicity and geographical origin for cases and controls was self-reported. All the participants were included in the study after giving written informed consent. Table [1](#T1){ref-type="table"} summarizes the characteristics of the individuals included in the study. The protocol was approved by the Ethics Committees of the University Hospitals "Príncipe de Asturias" and "Infanta Cristina" (Badajoz). The study was conducted according to the principles expressed in the declaration of Helsinki.

###### 

Characteristics of the individuals included in the study

                                                                          **Overall MS patients**   **RRMS**      **SPMS**      **PPMS**      **Control individuals**
  ----------------------------------------------------------------------- ------------------------- ------------- ------------- ------------- -------------------------
  Gender (females/males)                                                  200/90                    111/44        59/33         30/13         213/97
  Age (mean ± SD)                                                         43.8 ± 11.3               40.0 ± 10.5   47.2 ± 9.9    54.4 ± 10.2   43.7 ± 12.2
  Age at onset (mean ± SD)                                                32.6 ± 10.6               29.5 ± 8.5    34.9 ± 11.8   43.4 ± 11.6   \-
  Disease duration (mean ± SD)                                            11.2 ± 7.9                10.5 ± 8.2    12.3 ± 9.3    11.0 ± 7.7    \-
  Expanded disability status scale (EDSS) (median, Interquartile range)   3.0, 4.50                 2.5, 2.00     6.5, 0.90     7.5, 0.50     \-
  Progression index (EDSS/MS duration)                                    0.5 ± 0.4                 0.3 ± 0.2     0.6 ± 0.5     0.7 ± 0.4     \-

RRMS Relapsing remitting Multiple Sclerosis. SPMS Secondary Progressive Multiple Sclerosis. PPMS Primary Progressive Multiple Sclerosis.

Genotyping of rs1800566 polymorphism
------------------------------------

Genotyping for *rs1800566* was performed in genomic DNA obtained from venous blood samples of participants using *TaqMan* Assays (C\_\_\_2091255_30, Life Technologies, Alcobendas, Madrid, Spain). Detection was carried out by qPCR in an Eppendorf realplex thermocycler. The amplification conditions were as follows: after a denaturation time of 10 min at 96°C, 45 cycles of 92°C 15 sec 60°C 90 sec were carried out and fluorescence was measured at the end of each cycle and at endpoint. All samples were determined in triplicate and genotypes were assigned both by gene identification software (RealPlex 2.0, Eppendorf, Madrid, Spain) and by analysis of the reference cycle number for each fluorescence curve, calculated by the use of the CalQPlex algorithm (Eppendorf, Madrid, Spain).

Statistical analysis
--------------------

Hardy-Weinberg equilibrium (HWE) both in MS patient and control groups was analyzed by the DeFinetti software (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). Allele and genotype frequency analysis was performed with SPSS ver. 17.

For categorical variables the intergroup comparison values were calculated using the chi-square or Fisher's exact tests when appropriate. For continuous variables, the Kolmogorov-Smirnoff test was used to analyze normality in the distribution. Then, the Student two sample *t* test was used for variables that followed a normal distribution (age and age at onset); the Mann--Whitney test was used for the duration of disease and the severity scores expanded disability status scale and progression index, because no normal distribution was observed for this parameter. The association between the genotypes and the risk of developing MS was assessed by two-way contingency table analysis (<http://statpages.org/ctab2x2.html>). Statistical power was calculated for the sample size of this study (this was determined from allele frequencies with a genetic model analyzing the frequency for carriers of the disease gene with Odds ratio (OR) = 1.5, p = 0.05 \[[@B49]\]). Two-tailed and one-tailed associations of the risk with the variant allele for ORs of 1.5; 1.4; 1.3; 1.2; and 1.1; were, respectively: 84.6% and 90.9%; 68.9% and 79.0%; 47.4% and 59.8%; 25.6% and 36.6%; and 9.9% and 16.56%.

Results
=======

The frequencies of *NQO1* rs1800566 genotypes and allelic variants in patients diagnosed with MS did not differ from those of controls (Table [2](#T2){ref-type="table"}). The genotype and allele frequencies in MS patients and healthy subjects were in Hardy-Weinberg's equilibrium. Mean age at onset of MS did not differ significantly between patients carrying *NQO1* rs1800566 C/C (mean ± SD = 32.1 ± 10.2 years, reference), C/T (mean ± SD = 33.5 ± 11.6 years, p = 0.220) and T/T (mean ± SD = 32.4 ± 12.0 years, p = 0.270). Association between the rs1800566 variant and MS risk was not observed when analyzing gender separately (Table [2](#T2){ref-type="table"}). The distribution of the *NQO1* rs1800566 genotype and allelic frequencies did not differ between each MS clinical evolutive type and controls (Table [3](#T3){ref-type="table"}) or in the severity scores: Expanded Disability Status Score or EDSS (p = 0.508 and p = 0.370 for heterozygous and homozygous carriers of the minor allele, respectively, as compared with homozygous carriers of the major allele) or progression index (p = 0.872 and p = 0.673 for heterozygous and homozygous carriers of the minor allele, respectively, as compared with homozygous carriers of the major allele).

###### 

***NQO1 rs1800566*genotype and allelic variants of patients with multiple sclerosis (MS) and healthy volunteers**

                           **MS PATIENTS N (%, 95% C.I.)**   **CONTROLS N (%, 95% C.I.)**   **Intergroup comparison values OR (%, 95% C.I.) P**   **MS WOMEN N (%, 95% C.I.)**   **CONTROL WOMEN N (%, 95% C.I.)**   **Intergroup comparison values OR (%, 95% C.I.) P**   **MS MEN N (%, 95% C.I.)**   **CONTROL MEN (N (%, 95% C.I.)**   **Intergroup comparison values OR (95% CI) P**
  ------------------------ --------------------------------- ------------------------------ ----------------------------------------------------- ------------------------------ ----------------------------------- ----------------------------------------------------- ---------------------------- ---------------------------------- ------------------------------------------------
  rs1800566 GENOTYPE C/C   178 (61.4, 55.8-67.0)             195 (62.9, 57.5-68.3)          Reference                                             120 (60.0, 53.2-66.8)          134 (62.9, 56.4-69.4)               Reference                                             58 (64.4, 54.6-74.3)         61 (62.9, 53.3-72.5)               Reference
  C/T                      99 (34.1, 28.7-39.6)              104 (33.5, 28.3-38.8)          1.43 (0.74-1.47), 0.810                               72 (36.0, 29.3-42.7)           72 (33.8, 27.5-40.2)                1.12 (0.74-1.68), 0.597                               27 (30.0, 20.5-39.5)         32 (33.0, 23.6-42.3)               0.88 (0.48-1.66), 0.708
  T/T                      13 (4.5, 2.1-6.9)                 11 (3.5, 1.5-5.6)              1.30 (0.57-2.96), 0.540                               8 (4.0, 1.3-6.7)               7 (3.3, 0.9-5.7)                    1.28 (0.45-3.63), 0.646                               5 (5.6, 0.8-10.3)            4 (4.1, 0.2-8.1)                   1.32 (0.34-5.14), 0.693
  Total                    290                               310                                                                                  200                            213                                                                                       90                           97                                  
  Allele C                 455 (78.4, 75.1-81.8)             494 (79.7, 76.5-82.8)          Reference                                             312 (78.0, 73.9-82.1)          340 (79.8, 76.0-83.6)               Reference                                             143 (79.4, 73.5-85.3)        154 (79.4, 73.7-85.1)              Reference
  Allele T                 125 (21.6, 18.2-24.9)             126 (20.3, 17.2-23.5)          1.08 (0.82-1.42), 0.601                               88 (22.0, 17.9-26.1)           86 (20.2, 16.4-24.0)                1.12 (0.80-1.56), 0.523                               37 (20.6, 14.7-26.5)         40 (20.6, 14.9-26.3)               1.00 (0.60-1.65), 0.988
  Total alleles            580                               620                                                                                  400                            426                                                                                       180                          194                                 

Major alleles and genotypes were assumed as reference values. P values correspond to logistic regression analyses.

###### 

***NQO1 rs1800566*genotype and allelic variants in patients with multiple sclerosis (MS), and relation with the clinical evolutive type of MS**

                           **BOUT ONSET MS (RELAPSING REMITTING PLUS SECONDARY PROGRESSIVE MS) N**   **Intergroup comparison values OR (95% CI), P**   **PRIMARY PROGRESSIVE MS N (%, 95% C.I.)**   **Intergroup comparison values OR (95% CI), P**   **CONTROLS N (%, 95% C.I.)**
  ------------------------ ------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------- ------------------------------------------------- ------------------------------
  rs1800566 GENOTYPE C/C   153 (61.9; 55.9-68.0)                                                     Reference                                         25 (58.1, 43.4-72.9)                         Reference                                         195 (62.9, 57.5-68.3)
  C/T                      85 (34.4; 28.5-40.3)                                                      1.04 (0.72-1.51); 0.822                           14 (32.6, 18.6-46.6)                         1.05 (0.52-2.11), 0.891                           104 (33.5, 28.3-38.8)
  T/T                      9 (3.6; 1.3-6.0)                                                          1.04 (0.39-2.79); 0.928                           4 (9.3, 0.6-18.0)                            2.84 (0.84-9.59), 0.081                           11 (3.5, 1.5-5.6)
  Total                    247                                                                                                                         43                                                                                             310
  Allele C                 391 (79.1; 75.6-82.7)                                                     Reference                                         64 (74.4, 65.2-83.6)                         Reference                                         494 (79.7, 76.5-82.8)
  Allele T                 103 (20.9; 17.3-24.4)                                                     1.03 (0.76-1.40); 0.829                           22 (25.6, 16.4-34.8)                         1.35 (0.80-2.27), 0.262                           126 (20.3, 17.2-23.5)
  Total alleles            494                                                                                                                         86                                                                                             620

All subgroups were compared with control subjects. Major alleles and genotypes were assumed as reference values. P values correspond to logistic regression analyses.

Discussion
==========

In contrast with the findings in the study by Stavropoulou et al. \[[@B42]\], we did not find significant differences either in the frequencies of rs1800566 genotypes, or in the frequencies of the allelic variants of this polymorphism in patients with MS when compared with healthy controls. In addition, rs1800566 polymorphism was neither associated with age at onset of MS, nor with clinical type of MS. Patient sample size and statistical power are higher in our study than in the study by Stavropoulou et al. \[[@B42]\].

A possible reason for the discrepancies between the study by Stavropoulou et al. \[[@B42]\] and the present one is the fact that the genotype distribution in the control group of the Stavropoulou et al. \[[@B42]\] study was in Hardy-Weinberg's disequilibrium (Pearson's p = 0.0086). The Hardy-Weinberg's disequilibrium was attributable to the female control group of the study by Stavropoulou et al. \[[@B42]\]. Another putative difference is that in the study by Stavropoulou et al. \[[@B42]\] the genotyping analysis was carried out by using qPCR melting curves, whereas in our study TaqMan genotyping was used.

Several SNPs have been described within the *NQO1* gene. It should be noted that most association studies on *NQO1* focusing on the SNP analyzed in this study show a relatively high minor allele frequency (about 20% for Caucasian populations according to 1000 genomes). The rs1800566 analyzed in this study is common in Caucasian individuals; in fact it occurs in all human populations, and is classified as a pathogenic allele related with altered susceptibility to benzene toxicity and response to chemotherapy (see [http://browser.1000genomes.org/Homo_sapiens/Variation/Phenotype?db=core;r=16:69744645--69745645;v=rs1800566;vdb=variation;vf=1366399](http://browser.1000genomes.org/Homo_sapiens/Variation/Phenotype?db=core;r=16:69744645–69745645;v=rs1800566;vdb=variation;vf=1366399)).

The present study has some limitations. First, the size of the analyzed cohorts may not be sufficient for strict conclusions about the role of *NQO1*in MS (though adequate to detect an OR as small as 1.5, a more modest association would not be detected). Secondly, because the cohort study included MS patients with different degrees of severity, it is not adequate for the investigation of the influence of *NQO1* genotypes on disability or severity of MS. The ideal study for this purpose should be prospective, including the genotyping of patients with a recent diagnosis of MS and a re-examination of the same patient cohort after similar long-term follow-up periods to establish evolutive type).

Conclusions
===========

Taking in account the limitations of the present study, the results suggest that, in contrast with the Stavropoulou et al. \[[@B42]\] report, *NQO1* rs1800566 genotypes and allelic variants are not associated with the risk for MS in Caucasian Spanish people. The fact that this particular SNP showed lack of association with MS risk in the present study does not exclude the possibility that other SNPs in the *NQO1* gene could be associated with a modification in the risk of this disease.
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